| Stereochemistry | RACEMIC |
| Molecular Formula | C21H26NO3 |
| Molecular Weight | 340.436 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
C[N+]1(C)CCCC(C1)OC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=GKNPSSNBBWDAGH-UHFFFAOYSA-N
InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
Mepenzolate is a postganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. It specifically antagonizes muscarinic receptors. Mepenzolate is marketed under the brand name CANTIL. CANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been
shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or
preventing complications.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
The usual adult dose is 1 or 2 tablets (25 or 50 mg) 4 times a day preferably with meals and at bedtime.
Route of Administration:
Oral
Mepenzolate (10(-8)-10(-5) M), a specific muscarinic receptor antagonist, antagonized contractions of the longitudinal muscle of the isolated guinea-pig ileum preparation elicited by the aqueous extracts of Mareya micrantha suggesting that the cholinergic ingredient(s) in the extract are acting at the muscarinic receptors of the preparation.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
